Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck in Supply Agreement With Canada for Antiviral Medicine for Covid-19

12/03/2021 | 02:45pm EST

By Michael Dabaie

Merck & Co. Inc. said it is in a supply agreement with the Canadian government for up to 1 million patient courses of molnupiravir, its investigational oral antiviral medicine for the treatment of Covid-19.

Merck is developing molnupiravir in collaboration with Ridgeback Biotherapeutics.

The government of Canada secured access in 2022 to 500,000 patient courses, with options for up to 500,000 more, pending Health Canada approval.

In November, Merck Canada filed the final wave of the molnupiravir rolling submission to Health Canada, which will decide on the therapy's approval when all necessary evidence has been reviewed.

The U.S. Food and Drug Administration's Antimicrobial Drugs Advisory Committee recently voted 13-10 that the known and potential benefits of molnupiravir outweigh its known and potential risks for the treatment of mild to moderate Covid-19 in high-risk adult patients. While the FDA isn't bound by the committee's guidance, it takes that advice into consideration.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

12-03-21 1445ET

All news about MERCK & CO., INC.
01/21Strides and its African subsidiary Universal Corporation partner with Medicines Patent
AQ
01/21Eisai - Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib..
AQ
01/21Merck - RESULTS FROM PIVOTAL PHASE 3 KEYNOTE-775/STUDY 309 TRIAL OF KEYTRUDA (PEMBROLIZ..
AQ
01/20Merck COVID-19 Antiviral Pill Licensed to 27 Manufacturers for Distribution in Poor, Mi..
MT
01/20Merck's $1.4 Billion Insurance Win won't be possible any more with Lloyd's cyber war ex..
AQ
01/20CASI Pharmaceuticals Says BioInvent Secured US Orphan Drug Designation for Follicular L..
MT
01/20International Flavors Taps Merck's Clyburn as Next CEO
DJ
01/20International Flavors & Fragrances Appoints Merk Executive Frank Clyburn as Chief Execu..
MT
01/20Merck senior executive Clyburn to leave for top job at chemicals firm IFF
RE
01/20Results From Pivotal Phase 3 KEYNOTE-775/Study 309 Trial of KEYTRUDA« (pembrolizumab) P..
BU
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 458 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 019 M - -
P/E ratio 2021 17,1x
Yield 2021 3,27%
Capitalization 202 B 202 B -
EV / Sales 2021 4,52x
EV / Sales 2022 3,78x
Nbr of Employees 73 500
Free-Float 70,6%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 79,98 $
Average target price 92,27 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.4.36%202 025
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356